Medical Devices
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global medical device regulatory pathways, market trends, and innovation impacting pharmaceutical R&D and commercialization.
Showing 1–12 of 18 articles
Quick answer
NovaPharmaNews Medical Devices hub for EMA covers 18 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
European Commission Opens 2026 Joint Scientific Consultation Submission Window
CVRx Enrolls First Patient in BENEFIT-HF Heart Failure Trial Testing Barostim Device
Smartee Denti-Technology Advances Mandibular Repositioning Technology at European Aligner Society Congress 2026
Cerus Corporation INTERCEPT Blood System Advances Through European Regulatory Review and Phase 3 Trials
FDA Real-World Evidence Framework Shifts $10B Toward Validated Medtech Platforms Like VentriPoint
SQ Innovation's Lasix ONYU Receives CE Marking Approval, Advances Toward European Market Authorization
Advanced Bifurcation Systems Acquires Svelte Medical Systems in Major Coronary Stent Deal
Boston Scientific Corporation Faces Securities Class Action Lawsuit with May 4 Deadline for Investors
Guerbet's Lipiodol Ultra Fluid Achieves EU Regulatory Milestone for Vascular Embolization Procedures
Femasys Launches FemaSeed Complete Fertility Solution for OB/GYNs at ACOG 2026
Mauna Kea Technologies Secures CE Mark Under New MDR, Expands European Medical Device Approvals
Boston Scientific Reports Strong Q1 2026 Growth with 10.9% US Sales Increase and Clinical Trial Breakthroughs
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.